These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
137 related articles for article (PubMed ID: 2360919)
1. Effect of probucol treatment on the susceptibility of low density lipoprotein isolated from hypercholesterolemic patients to become oxidatively modified in vitro. Regnström J; Walldius G; Carlson LA; Nilsson J Atherosclerosis; 1990 May; 82(1-2):43-51. PubMed ID: 2360919 [TBL] [Abstract][Full Text] [Related]
2. The effect of probucol on low density lipoprotein oxidation and femoral atherosclerosis. Regnström J; Walldius G; Nilsson S; Elinder LS; Johansson J; Mölgaard J; Holme I; Olsson AG; Nilsson J Atherosclerosis; 1996 Sep; 125(2):217-29. PubMed ID: 8842353 [TBL] [Abstract][Full Text] [Related]
3. The role of lipids and antioxidative factors for development of atherosclerosis. The Probucol Quantitative Regression Swedish Trial (PQRST). Walldius G; Regnström J; Nilsson J; Johansson J; Schäfer-Elinder L; Moelgaard J; Hådell K; Olsson AG; Carlson LA Am J Cardiol; 1993 Feb; 71(6):15B-19B. PubMed ID: 8434556 [TBL] [Abstract][Full Text] [Related]
4. Effect of probucol dosage on plasma lipid and lipoprotein levels and on protection of low density lipoprotein against in vitro oxidation in humans. Reaven PD; Parthasarathy S; Beltz WF; Witztum JL Arterioscler Thromb; 1992 Mar; 12(3):318-24. PubMed ID: 1547191 [TBL] [Abstract][Full Text] [Related]
5. Probucol inhibits oxidative modification of low density lipoprotein. Parthasarathy S; Young SG; Witztum JL; Pittman RC; Steinberg D J Clin Invest; 1986 Feb; 77(2):641-4. PubMed ID: 3944273 [TBL] [Abstract][Full Text] [Related]
6. Effectiveness of probucol in reducing plasma low-density lipoprotein cholesterol oxidation in hypercholesterolemia. Masana L; Bargalló MT; Plana N; LaVille A; Casals I; Solà R Am J Cardiol; 1991 Oct; 68(9):863-7. PubMed ID: 1927944 [TBL] [Abstract][Full Text] [Related]
7. Probucol and cholestyramine combination in the treatment of severe hypercholesterolemia. Sommariva D; Bonfiglioli D; Tirrito M; Pogliaghi I; Branchi A; Cabrini E Int J Clin Pharmacol Ther Toxicol; 1986 Sep; 24(9):505-10. PubMed ID: 3781686 [TBL] [Abstract][Full Text] [Related]
8. Concentration-dependent antioxidant activity of probucol in low density lipoproteins in vitro: probucol degradation precedes lipoprotein oxidation. Barnhart RL; Busch SJ; Jackson RL J Lipid Res; 1989 Nov; 30(11):1703-10. PubMed ID: 2614272 [TBL] [Abstract][Full Text] [Related]
9. The in vitro and ex vivo antioxidant properties, and hypolipidemic activity of CGP 2881. Feldman DL; Mogelesky TC; Sharif R; Sawyer WK; Jeune M; Hu CW; Leonards KS; Prescott MF Atherosclerosis; 1999 Jun; 144(2):343-55. PubMed ID: 10407495 [TBL] [Abstract][Full Text] [Related]
10. Probucol: effects on the metabolism of low density and high density lipoproteins in moderate hypercholesterolaemia. Magill P; Whiting C; Hammett F; Glick I; Miller NE; Lewis B Artery; 1982; 10(2):88-94. PubMed ID: 7092581 [TBL] [Abstract][Full Text] [Related]
11. Studies on the mechanism of action of probucol. Steinberg D Am J Cardiol; 1986 Jun; 57(16):16H-21H. PubMed ID: 3728306 [TBL] [Abstract][Full Text] [Related]
12. Influence of probucol on enhanced LDL oxidation after fish oil treatment of hypertriglyceridemic patients. Lussier-Cacan S; Dubreuil-Quidoz S; Roederer G; Leboeuf N; Boulet L; de Langavant GC; Davignon J; Naruszewicz M Arterioscler Thromb; 1993 Dec; 13(12):1790-7. PubMed ID: 8241099 [TBL] [Abstract][Full Text] [Related]
13. Inhibition of low density lipoprotein oxidation by thyronines and probucol. Hanna AN; Feller DR; Witiak DT; Newman HA Biochem Pharmacol; 1993 Feb; 45(3):753-62. PubMed ID: 8442772 [TBL] [Abstract][Full Text] [Related]
14. Effect of probucol on macrophages, leading to regression of xanthomas and atheromatous vascular lesions. Yamamoto A; Hara H; Takaichi S; Wakasugi J; Tomikawa M Am J Cardiol; 1988 Jul; 62(3):31B-36B. PubMed ID: 3394651 [TBL] [Abstract][Full Text] [Related]
15. Structural changes in oxidised low-density lipoproteins and of the effect of the anti-atherosclerotic drug probucol observed by synchrotron X-ray and neutron solution scattering. Bellamy MF; Nealis AS; Aitken JW; Bruckdorfer KR; Perkins SJ Eur J Biochem; 1989 Aug; 183(2):321-9. PubMed ID: 2759086 [TBL] [Abstract][Full Text] [Related]
16. Low-dose colestipol plus probucol for hypercholesterolemia. Dujovne CA; Chernoff SB; Krehbiel P; Jackson B; DeCoursey S; Taylor H Am J Cardiol; 1984 Jun; 53(11):1514-8. PubMed ID: 6375337 [TBL] [Abstract][Full Text] [Related]
17. Antiatherogenic effect of probucol unrelated to its hypocholesterolemic effect: evidence that antioxidants in vivo can selectively inhibit low density lipoprotein degradation in macrophage-rich fatty streaks and slow the progression of atherosclerosis in the Watanabe heritable hyperlipidemic rabbit. Carew TE; Schwenke DC; Steinberg D Proc Natl Acad Sci U S A; 1987 Nov; 84(21):7725-9. PubMed ID: 3478721 [TBL] [Abstract][Full Text] [Related]
18. Differing effects of probucol and vitamin E on the oxidation of lipoproteins, ceroid accumulation and protein uptake by macrophages. Hunt JV; Bottoms MA; Taylor SE; Lyell V; Mitchinson MJ Free Radic Res; 1994 Mar; 20(3):189-201. PubMed ID: 8019642 [TBL] [Abstract][Full Text] [Related]
19. Effect of probucol on serum lipoprotein levels in normal and dyslipoproteinemic mice. Tomikawa M; Nakayasu T; Tawara K; Abiko Y Atherosclerosis; 1981 Oct; 40(2):101-13. PubMed ID: 6946776 [TBL] [Abstract][Full Text] [Related]